ArticleIranian journal of child neurology2026
The Effect of Gluten-Free Diet on Gastrointestinal Symptoms and Disease Severity of Autistic Children: A Randomized Controlled Trial.
Article in Iranian journal of child neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Autism Sspectrum Disorder (ASD) is a kind of neurodevelopmental disease characterized by difficulties in social interactions, verbal and non-verbal communication, movement limitations, and repetitive movement patterns. The goal of this study is to investigate the effects of a Gluten-Free Diet (GFD) on gastrointestinal (GI) and neurological symptoms in patients diagnosed with autism. Materials & Methods: In this study, 120 patients with autism from Tabriz Children's Hospital and Sheikh Al-Rais Clinic were included. Neurologists and psychologists confirmed the diagnosis of autism using the M-CHAT-R/F questionnaire. Based on the patients' clinical history and Rome 3 criteria, GI symptoms such as diarrhea, constipation, vomiting, and abdominal discomfort were detected. A Gluten Free Diet was advised, and the parents received nutrition education and ongoing autism therapies. The control group consisted of children who received specialized medications for autism while maintaining a regular diet. These children were monitored closely. Results: The average age of the patients was 9.27 ± 3.25 years with a median of nine years. Fifty-two patients (47.3%) were boys, and fifty-eight patients (52.7%) were girls. The severity of ASD, as measured by the M-CHAT-R/F scale, was significantly reduced at the 12th month in the intervention group. Furthermore, significant improvements in speech, cognition, and behavior have been observed in patients in the intervention group after using a GFD. Moreover, GI symptoms, including nausea and vomiting, constipation, abdominal pain, and discomfort, were significantly decreased in the intervention group. However, the GI symptoms in the control group did not show any statistically significant difference compared to the 12th month. Conclusion: According to the results obtained in this study, the administration of GFD in children with ASD can significantly lead to the improvement of GI disorders and neurological symptoms regarding the severity of autism in speech, cognition, and behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.